Clinical relevance of brain atrophy subtypes categorization in memory clinics.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
04 2021
Historique:
revised: 14 10 2020
received: 07 07 2020
accepted: 19 10 2020
pubmed: 17 12 2020
medline: 4 11 2021
entrez: 16 12 2020
Statut: ppublish

Résumé

The clinical relevance of brain atrophy subtypes categorization in non-demented persons without a priori knowledge regarding their amyloid status or clinical presentation is unknown. A total of 2083 outpatients with either subjective cognitive complaint or mild cognitive impairment at study entry were followed during 4 years (MEMENTO cohort). Atrophy subtypes were defined using baseline magnetic resonance imaging (MRI) and previously described algorithms. Typical/diffuse atrophy was associated with faster cognitive decline and the highest risk of developing dementia and Alzheimer's disease (AD) over time, both in the whole analytic sample and in amyloid-positive participants. Hippocampal-sparing and limbic-predominant atrophy were also associated with incident dementia, with faster cognitive decline in the limbic predominant atrophy group. Lewy body dementia was more frequent in the hippocampal-sparing and minimal/no atrophy groups. Atrophy subtypes categorization predicted different subsequent patterns of cognitive decline and rates of conversion to distinct etiologies of dementia in persons attending memory clinics.

Identifiants

pubmed: 33325121
doi: 10.1002/alz.12231
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

641-652

Informations de copyright

© 2021 the Alzheimer's Association.

Références

Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: a systematic review and meta-analysis. Neurology. 2020;94:436-448.
Ossenkoppele R, Lyoo CH, Sudre CH, et al. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. Alzheimers Dement. 2019;16(2):335-344.
Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol. 2012;11:868-877.
Byun MS, Kim SE, Park J, et al. Heterogeneity of regional brain atrophy patterns associated with distinct progression rates in Alzheimer's disease. PLoS ONE. 2015;10:e0142756.
Risacher SL, Anderson WH, Charil A, et al. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology. 2017;89:2176-2186.
Dong A, Toledo JB, Honnorat N, et al. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers. Brain. 2017;140:735-747.
Ferreira D, Verhagen C, Hernández-Cabrera JA, et al. Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Sci Rep. 2017;7:46263.
Ten Kate M, Dicks E, Visser PJ, et al. Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. Brain. 2018;141:3443-3456.
Kim HJ, Park J-Y, Seo SW, et al. Cortical atrophy pattern-based subtyping predicts prognosis of amnestic MCI: an individual-level analysis. Neurobiol Aging. 2019;74:38-45.
Park J-Y, Na HK, Kim S, et al. Robust identification of Alzheimer's disease subtypes based on cortical atrophy patterns. Sci Rep. 2017;7:43270.
Poulakis K, Pereira JB, Mecocci P, et al. Heterogeneous patterns of brain atrophy in Alzheimer's disease. Neurobiol Aging. 2018;65:98-108.
Na HK, Kang DR, Kim S, et al. Malignant progression in parietal-dominant atrophy subtype of Alzheimer's disease occurs independent of onset age. Neurobiol Aging. 2016;47:149-156.
Hwang J, Kim CM, Jeon S, et al. Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns. Alzheimers Dement (Amst). 2016;2:58-67.
Dufouil C, Dubois B, Vellas B, et al. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimers Res Ther. 2017;9:67.
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88-100.
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456-2477.
Operto G, Chupin M, Batrancourt B, et al. CATI: a large distributed infrastructure for the neuroimaging of cohorts. Neuroinformatics. 2016;14:253-264.
Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839-851.
Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341-355.
Chupin M, Hammers A, Liu RSN, et al. Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: method and validation. Neuroimage. 2009;46:749-761.
Samaille T, Fillon L, Cuingnet R, et al. Contrast-based fully automatic segmentation of white matter hyperintensities: method and validation. PLoS ONE. 2012;7:e48953.
Habert M-O, Bertin H, Labit M, et al. Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. Ann Nucl Med. 2018;32:75-86.
Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785-796.
Vivot A, Power MC, Glymour MM, et al. Jump, hop, or skip: modeling practice effects in studies of determinants of cognitive change in older adults. Am J Epidemiol. 2016;183:302-314.
Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109-2123.
Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535-562.
Oppedal K, Ferreira D, Cavallin L, et al. A signature pattern of cortical atrophy in dementia with Lewy bodies: a study on 333 patients from the European DLB consortium. Alzheimers Dement. 2019;15:400-409.
Josephs KA, Whitwell JL, Tosakulwong N, et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. Ann Neurol. 2015;78:697-709.
Jellinger KA. Neuropathological subtypes of Alzheimer's disease. Acta Neuropathol. 2012;123:153-154.
Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012;11:1006-1012.
Benvenutto A, Giusiano B, Koric L, et al. Imaging biomarkers of neurodegeneration in Alzheimer's disease: distinct contributions of cortical MRI atrophy and FDG-PET hypometabolism. J Alzheimers Dis. 2018;65:1147-1157.
Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503-1527.
Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer's disease. Lancet. 2016;388:505-517.
Planche V, Coupé P, Helmer C, et al. Evolution of brain atrophy subtypes during aging predicts long-term cognitive decline and future Alzheimer's clinical syndrome. Neurobiol Aging. 2019;79:22-29.
Aziz A-L, Giusiano B, Joubert S, et al. Difference in imaging biomarkers of neurodegeneration between early and late-onset amnestic Alzheimer's disease. Neurobiol Aging. 2017;54:22-30.
Ferreira D, Pereira JB, Volpe G, Westman E. Subtypes of Alzheimer's disease display distinct network abnormalities extending beyond their pattern of brain atrophy. Front Neurol. 2019;10:524.
Goedert M. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. 2015;349:1255555.
Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci. 2018;21:1341-1349.

Auteurs

Vincent Planche (V)

Univ. Bordeaux, CNRS UMR 5293, Institut des Maladies Neurodégénératives, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.

Vincent Bouteloup (V)

Univ. Bordeaux, Inserm U1219, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Bordeaux, France.

Jean-François Mangin (JF)

Univ. Paris-Saclay, CEA, CNRS, Baobab, Neurospin, CATI multicenter neuroimaging platform, Gif-sur-Yvette, France.

Bruno Dubois (B)

Sorbonne-Université, Service des maladies cognitives et comportementales et Institut de la mémoire et de la maladie d'Alzheimer (IM2A), Hôpital de la Salpêtrière, AP-PH, Paris, France.

Julien Delrieu (J)

Departement de Gériatrie, Univ. Toulouse, Inserm U1027, Gérontopôle, CHU Purpan, Toulouse, France.

Florence Pasquier (F)

Univ. Lille, Inserm U1171, Centre Mémoire de Ressources et de Recherches, CHU Lille, DISTAlz, Lille, France.

Frédéric Blanc (F)

ICube laboratory, Departement de Gériatrie, Univ. Strasbourg, CNRS, UMR 7357, Fédération de Médecine Translationnelle de Strasbourg, Centre Mémoire de Ressources et de Recherches, Strasbourg, France.

Claire Paquet (C)

Univ. Paris, Inserm U1144, Groupe Hospitalier Lariboisière Fernand-Widal, AP-HP, Paris, France.

Olivier Hanon (O)

Univ. Paris Descartes Sorbonne Paris Cité, EA 4468, Service de Gériatrie, AP-HP, Hôpital Broca, Paris, France.

Audrey Gabelle (A)

Département de Neurologie, Univ. Montpellier, i-site MUSE, Inserm U1061, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences, CHU de Montpellier, Montpellier, France.

Matthieu Ceccaldi (M)

Département de Neurologie et de Neuropsychologie, Univ. Aix Marseille, Inserm UMR 1106, Institut de Neurosciences des Systèmes, Centre Mémoire de Ressources et de Recherches, AP-HM, Marseille, France.

Cédric Annweiler (C)

Département de Gériatrie, CHU d'Angers, Univ. Angers, UPRES EA 4638, Centre Mémoire de Ressources et de Recherches, Angers, France.

Pierre Krolak-Salmon (P)

Univ. Lyon, Inserm U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, Centre Mémoire Ressource et Recherche de Lyon (CMRR), Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France.

Marie-Odile Habert (MO)

Laboratoire d'Imagerie Biomédicale, Sorbonne-Université, CNRS, Inserm, CATI multicenter neuroimaging platform, AP-HP, Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France.

Clara Fischer (C)

Univ. Paris-Saclay, CEA, CNRS, Baobab, Neurospin, CATI multicenter neuroimaging platform, Gif-sur-Yvette, France.

Marie Chupin (M)

Sorbonne-Université, Inserm U1127, CNRS UMR 7225, CATI multicenter neuroimaging platform, Institut du Cerveau et de la Moelle épinière, Paris, France.

Yannick Béjot (Y)

Univ. Bourgogne, EA7460, Centre Mémoire de Ressources et de Recherches, CHU Dijon Bourgogne, Dijon, France.

Olivier Godefroy (O)

Laboratoire de Neurosciences Fonctionnelles et Pathologies, Univ. Picardie, UR UPJV4559, Service de Neurologie, CHU Amiens, Amiens, France.

David Wallon (D)

Departement de Neurologie, Univ. Normandie, UNIROUEN, Inserm U1245, CNR-MAJ, CHU de Rouen, Rouen, France.

Mathilde Sauvée (M)

Centre Mémoire de Ressources et de Recherches Grenoble Arc Alpin, Pôle de Psychiatrie et Neurologie, CHU Grenoble, Grenoble, France.

Isabelle Bourdel-Marchasson (I)

Univ. Bordeaux, Inserm U1219, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Bordeaux, France.
Univ. Bordeaux, CNRS UMR 5536, Centre de Résonance Magnétique des Systèmes Biologiques, Pole de gérontologie clinique, CHU de Bordeaux, Bordeaux, France.

Isabelle Jalenques (I)

Univ. Clermont Auvergne, Centre Mémoire de Ressources et de Recherches, CHU de Clermont-Ferrand, Clermont-Ferrand, France.

François Tison (F)

Univ. Bordeaux, CNRS UMR 5293, Institut des Maladies Neurodégénératives, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.

Geneviève Chêne (G)

Univ. Bordeaux, Inserm U1219, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Pôle de Sante Publique, CHU de Bordeaux, Bordeaux, France.

Carole Dufouil (C)

Univ. Bordeaux, Inserm U1219, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Pôle de Sante Publique, CHU de Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH